Diagnosis and Treatment of Tuberculosis

Diagnostic Approach

The American College of Chest Physicians recommends collecting three sputum specimens on different days for AFB smear microscopy, mycobacterial culture, and nucleic acid amplification testing (NAAT) in any patient with cough ≥3 weeks, particularly when accompanied by evening fever, night sweats, weight loss, or hemoptysis 1
Maintain a lower threshold for suspicion in high-risk populations: HIV-infected, immunosuppressed, foreign-born from endemic countries, homeless, and incarcerated individuals 1
Classic symptoms include cough ≥3 weeks, evening fever, night sweats, weight loss, anorexia, and hemoptysis 1
Chest radiography should show apical cavitary lesions, infiltrates, lymphadenopathy, or pleural effusions, though findings may be atypical in immunocompromised patients 1, 2

Collect three sputum specimens 8-24 hours apart, with at least one early morning specimen, as the first specimen has 53.8% sensitivity, the second adds 11.1%, and the third adds only 2-5% additional yield 2, 3
Use sputum induction with hypertonic saline aerosol in patients unable to produce adequate sputum 3
First morning specimens are 12% more sensitive than spot specimens, and concentrated specimens increase sensitivity by 18% 2
Fluorescence microscopy is 10% more sensitive than conventional microscopy 2
Process all specimens for AFB smear microscopy, mycobacterial culture (both liquid and solid media), and NAAT on at least the first diagnostic specimen 1, 2, 3
Culture remains the gold standard for diagnosis, species identification, and drug susceptibility testing 1, 3
NAAT (GeneXpert MTB/RIF) provides results within 1 day and simultaneously detects rifampin resistance, with 96.3% sensitivity and 81.3% specificity in smear-negative cases 2
Three AFB smears have approximately 70% sensitivity when culture-confirmed TB is the reference standard, but 40% of culture-positive cases are smear-negative 2, 3

The American Thoracic Society recommends initiating isoniazid, rifampin, pyrazinamide, and ethambutol (HREZ) for 2 months followed by isoniazid and rifampin for 4 additional months (total 6 months) in all new cases of drug-susceptible pulmonary TB 4
Directly observed therapy (DOT) is recommended for all patients to ensure compliance and prevent drug-resistant TB 5
DOT involves observation of the patient by a healthcare provider or responsible person as the patient ingests anti-tuberculosis medications 5
A case manager should be assigned to each patient to ensure adequate education, continuous standard therapy, and contact evaluation 5
HIV-infected patients with culture-negative pulmonary TB should be treated for a minimum of 6 months 4
Specific dosing adjustments are required for patients with renal insufficiency and end-stage renal disease 4
Administer all drugs after hemodialysis to facilitate DOT and avoid premature drug removal 4
Monitor serum drug concentrations in patients with renal failure taking cycloserine or ethambutol 4
Treat with the same 6-month regimen as pulmonary disease for all sites except meninges 4
Tuberculous meningitis requires 9-12 months of treatment 4
Addition of corticosteroids is recommended for tuberculous pericarditis and tuberculous meningitis 4

Never rely on a single negative sputum specimen to exclude TB—three specimens are required 2, 3
Do not exclude TB based on negative AFB smears alone—40% of culture-positive cases are smear-negative 2, 3
Do not delay empiric treatment in high-suspicion cases while awaiting culture results 1, 2
Do not use TST or IGRA to diagnose active TB disease 2, 3
Always collect specimens for culture and drug susceptibility testing before starting treatment 2, 3